ZNF133 Is Associated with Infliximab Responsiveness in Patients with Inflammatory Bowel Diseases.

ZNF133 Is Associated with Infliximab Responsiveness in Patients with Inflammatory Bowel Diseases. J Gastroenterol Hepatol. 2019 Mar 09;: Authors: Jung ES, Choi KW, Kim SW, Hübenthal M, Mucha S, Park J, Park Z, Ellinghaus D, Schreiber S, Franke A, Oh WY, Cheon JH Abstract BACKGROUND AND AIM: Infliximab has been widely prescribed for treating inflammatory bowel disease (IBD). However, the response rates to infliximab differ among patients. Therefore, we aimed to identify the genetic and clinical markers that predict infliximab response. METHODS: A total of 139 Korean patients with IBD…

Read More

Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.

Related Articles Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol. 2019 Mar 03;: Authors: Kim NH, Lee JH, Hong SN, Yoon H, Kang HW, Lee SH, Im JP, Cha JM, Eun CS, Kim JW, Choi CH, Park DI Abstract BACKGROUND AND AIM: A biosimilar of infliximab, CT-P13 (Remsima®) has the potential to reduce treatment costs and enhance access to biological therapy for inflammatory bowel disease (IBD) patients. However, long-term clinical data on its use for…

Read More

Efficacy of Infliximab in Crohn’s Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.

Related Articles Efficacy of Infliximab in Crohn’s Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists. Dig Dis Sci. 2019 Feb 28;: Authors: Clark-Snustad KD, Singla A, Lee SD Abstract BACKGROUND: Tumor necrosis factor antagonists (TNFs) are effective for moderate-severe Crohn’s disease (CD). Approximately one-third of patients have primary-nonresponse to TNFs, which is reported to predict worse response to subsequent TNF therapy. However, this is based on treatment with subcutaneously (SC) administered, fixed-dose TNFs after failure of intravenously (IV) administered, weight-based TNFs. No study has specifically assessed the clinical…

Read More

Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy.

Related Articles Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy. J Crohns Colitis. 2019 Feb 27;: Authors: Panés J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, Flynn HA, Huyck S, Stryszak P, Yao R, Philip G, Reinisch W Abstract BACKGROUND AND AIMS: The Observational Postmarketing Ulcerative colitis Study (OPUS) was conducted to obtain the first long-term (5 years) safety data assessing treatment with originator infliximab versus conventional therapies in patients with ulcerative…

Read More

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed. Aliment Pharmacol Ther. 2019 Mar;49(6):816-817 Authors: Gibson DJ, Ward MG PMID: 30811645 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30811645?dopt=Abstract

Read More

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy – early promise but more data needed. Authors’ reply.

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy – early promise but more data needed. Authors’ reply. Aliment Pharmacol Ther. 2019 Mar;49(6):817-818 Authors: Bouguen G, Siproudhis L PMID: 30811643 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30811643?dopt=Abstract

Read More

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

Related Articles Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Feb 19;: Authors: Drobne D, Kurent T, Golob S, Švegl P, Rajar P, Hanžel J, Koželj M, Novak G, Smrekar N, Ferkolj I, Štabuc B Abstract BACKGROUND: Combination treatment with azathioprine for 6-12 months is the preferred strategy for starting infliximab due to improved pharmacokinetics. However, optimised infliximab monotherapy with proactive dose escalations in case of low trough levels is a safer but under-studied…

Read More

Long-term outcomes of patients with Crohn’s disease who received infliximab or adalimumab as the first-line biologics.

Long-term outcomes of patients with Crohn’s disease who received infliximab or adalimumab as the first-line biologics. J Gastroenterol Hepatol. 2019 Feb 06;: Authors: Inokuchi T, Takahashi S, Hiraoka S, Toyokawa T, Takagi S, Takemoto K, Miyaike J, Fujimoto T, Higashi R, Morito Y, Nawa T, Suzuki S, Nishimura M, Inoue M, Kato J, Okada H Abstract BACKGROUND AND AIM: Although previous studies compared the efficacy of infliximab (IFX) versus adalimumab (ADA) as the first-line biologics for Crohn’s disease (CD), the difference in long-term prognosis based on which biologic was used…

Read More

Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis.

Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis. J Crohns Colitis. 2019 Jan 23;: Authors: Church PC, Ho S, Sharma A, Tomalty D, Frost K, Muise A, Walters TD, Griffiths AM Abstract Background: Infliximab pharmacokinetics in steroid-refractory ulcerative colitis (UC) suggest a need for higher dosing, but data concerning efficacy of intensification in this setting are lacking in children and inconsistent overall. Methods: Paediatric patients (N=125) treated with infliximab for steroid-refractory or steroid-dependent UC were retrospectively reviewed. Outcomes (clinical response and remission,…

Read More
<< Go Back